Transforming anti-Alzheimer’s therapy by targeting endogenous receptorrial system through ligand-conjugated nanoformulations

IF 15.5 1区医学 Q1 CELL BIOLOGY

Ageing Research Reviews Pub Date : 2026-01-01 Epub Date: 2025-12-13 DOI:10.1016/j.arr.2025.102994

Madhuri Gawai , Neha Nistane , Amol A. Tatode , Mohammad Qutub , Milind J. Umekar , Tanvi Premchandani , Jayshree B. Taksande

{"title":"Transforming anti-Alzheimer’s therapy by targeting endogenous receptorrial system through ligand-conjugated nanoformulations","authors":"Madhuri Gawai , Neha Nistane , Amol A. Tatode , Mohammad Qutub , Milind J. Umekar , Tanvi Premchandani , Jayshree B. Taksande","doi":"10.1016/j.arr.2025.102994","DOIUrl":null,"url":null,"abstract":"<div><div>Alzheimer’s Disease (AD) is the most prevalent neurodegenerative disorder, contributing to the majority of dementia cases in the elderly globally. Characterized by progressive cognitive decline, AD is associated with complex neuropathological changes, including the accumulation of amyloid-beta (Aβ) plaques and tau tangles, synaptic loss, and neuroinflammation. One of the significant challenges in treating AD is the blood-brain barrier (BBB), which prevents many therapeutic agents from reaching the brain. Despite advancements in understanding AD's pathology, limited treatment options are available, largely due to the inability of conventional drugs to effectively target the brain. Ligand-conjugated nanoparticles (NPs) are promising for targeted drug delivery to the brain. These NPs, engineered with ligands that can bind to specific receptors or transporters on the BBB, facilitate the crossing of the barrier via receptor-mediated endocytosis or adsorptive-mediated transcytosis. This strategy enhances therapeutic agents' bioavailability and cellular uptake, offering a potential solution to overcome current limitations in AD treatment. Using nanotechnology to design ligand-conjugated NPs for targeted and sustained drug delivery could significantly improve therapeutic outcomes for AD patients by addressing key pathological processes in the brain.</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"114 ","pages":"Article 102994"},"PeriodicalIF":15.5000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ageing Research Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S156816372500340X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Alzheimer’s Disease (AD) is the most prevalent neurodegenerative disorder, contributing to the majority of dementia cases in the elderly globally. Characterized by progressive cognitive decline, AD is associated with complex neuropathological changes, including the accumulation of amyloid-beta (Aβ) plaques and tau tangles, synaptic loss, and neuroinflammation. One of the significant challenges in treating AD is the blood-brain barrier (BBB), which prevents many therapeutic agents from reaching the brain. Despite advancements in understanding AD's pathology, limited treatment options are available, largely due to the inability of conventional drugs to effectively target the brain. Ligand-conjugated nanoparticles (NPs) are promising for targeted drug delivery to the brain. These NPs, engineered with ligands that can bind to specific receptors or transporters on the BBB, facilitate the crossing of the barrier via receptor-mediated endocytosis or adsorptive-mediated transcytosis. This strategy enhances therapeutic agents' bioavailability and cellular uptake, offering a potential solution to overcome current limitations in AD treatment. Using nanotechnology to design ligand-conjugated NPs for targeted and sustained drug delivery could significantly improve therapeutic outcomes for AD patients by addressing key pathological processes in the brain.

查看原文本刊更多论文

通过配体共轭纳米制剂靶向内源性受体系统转化抗阿尔茨海默病治疗。

阿尔茨海默病（AD）是最普遍的神经退行性疾病，是全球老年人痴呆症病例的主要原因。AD以进行性认知能力下降为特征，与复杂的神经病理改变相关，包括淀粉样蛋白斑块和tau蛋白缠结的积累、突触丧失和神经炎症。治疗阿尔茨海默病的一个重大挑战是血脑屏障（BBB），它阻止许多治疗药物到达大脑。尽管对阿尔茨海默病病理的了解有所进展，但治疗选择有限，这主要是由于传统药物无法有效靶向大脑。配体共轭纳米颗粒（NPs）有望用于靶向药物输送到大脑。这些NPs经过配体改造，可以与血脑屏障上的特定受体或转运体结合，通过受体介导的内吞作用或吸附介导的胞吞作用促进屏障的跨越。这种策略提高了治疗剂的生物利用度和细胞摄取，为克服目前阿尔茨海默病治疗的局限性提供了一种潜在的解决方案。利用纳米技术设计配体共轭NPs用于靶向和持续的药物递送，可以通过解决大脑中的关键病理过程显着改善AD患者的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ageing Research Reviews 医学-老年医学

CiteScore

19.80

自引率

2.30%

发文量

216

审稿时长

55 days

期刊介绍： With the rise in average human life expectancy, the impact of ageing and age-related diseases on our society has become increasingly significant. Ageing research is now a focal point for numerous laboratories, encompassing leaders in genetics, molecular and cellular biology, biochemistry, and behavior. Ageing Research Reviews (ARR) serves as a cornerstone in this field, addressing emerging trends. ARR aims to fill a substantial gap by providing critical reviews and viewpoints on evolving discoveries concerning the mechanisms of ageing and age-related diseases. The rapid progress in understanding the mechanisms controlling cellular proliferation, differentiation, and survival is unveiling new insights into the regulation of ageing. From telomerase to stem cells, and from energy to oxyradical metabolism, we are witnessing an exciting era in the multidisciplinary field of ageing research. The journal explores the cellular and molecular foundations of interventions that extend lifespan, such as caloric restriction. It identifies the underpinnings of manipulations that extend lifespan, shedding light on novel approaches for preventing age-related diseases. ARR publishes articles on focused topics selected from the expansive field of ageing research, with a particular emphasis on the cellular and molecular mechanisms of the aging process. This includes age-related diseases like cancer, cardiovascular disease, diabetes, and neurodegenerative disorders. The journal also covers applications of basic ageing research to lifespan extension and disease prevention, offering a comprehensive platform for advancing our understanding of this critical field.